.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to improved progression-free and also general survival, triggering FDA approval as well as a new treatment option for people.